Clinical trial Recruiting at 2 sites Phase 4 Interventional Ages 0 Hours to 48 Hours

Pasteurised donor human milk for term babies born to mothers with diabetes

Official title: A Randomised Controlled Trial of Pasteurised Donor Human Milk as Supplementary Nutrition for Infants Born to Women With Diabetes in Pregnancy.

Run by The University of Queensland · NCT06993103 · Data updated 2026-11-12

This trial will try giving pasteurised donor human milk instead of formula to term infants of mothers with diabetes during the first five days to see if it reduces neonatal unit admissions for low blood sugar.

More Breastfeeding trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages0 Hours to 48 Hours
SexAll
Enrollment1444 (estimated)
SponsorThe University of Queensland
Academic / other
Drugs / interventionschemotherapy
Locations4 sites (Brisbane, Queensland and 3 other locations)
StatusRecruiting
StartedDecember 4, 2025
Main results expectedApril 2028
Study endsDecember 2028
Registry record updatedSeptember 2, 2026
Trial IDNCT06993103 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are mother–infant pairs where the mother is over 18 with diabetes in pregnancy, intends to breastfeed, and the term infant (≥37 weeks, >2.5 kg) requires supplementary nutrition within the first 48 hours after birth.

Probably not a fit

Pairs unlikely to benefit include those who do not need supplemental feeding, multiple pregnancies, mothers with contraindications to breastfeeding (e.g., HIV, chemotherapy), or infants with clinical conditions that exclude trial enrolment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PRESENT is a multi-center, randomized controlled trial comparing in-hospital pasteurised donor human milk (PDHM) supplementation versus local standard care (which may include cow's milk formula) for term infants born to women with type 1, type 2, or gestational diabetes. Eligible infants (≥37 weeks, >2.5 kg) whose clinician decides supplemental nutrition is needed within 48 hours of birth are randomized to receive PDHM until day 5 or to continue usual care per local policy. The primary outcome is the proportion of infants admitted to a neonatal unit for management of hypoglycaemia; secondary outcomes include breastfeeding rates, maternal mental health, and infant cow's milk allergy. Parents complete electronic questionnaires at 2 and 6 weeks and 6 and 12 months after birth to capture feeding and health outcomes.

Why it matters

Potential benefit: If successful, providing PDHM could reduce neonatal unit admissions for hypoglycaemia, lower early exposure to cow's milk formula, and improve breastfeeding and maternal well-being.

How similar studies have gone: PDHM has documented benefits in very preterm or very low birthweight infants, but using PDHM for term infants to prevent hypoglycaemia and reduce neonatal unit admissions is relatively novel and less well studied.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Each participant must meet all the following criteria to be enrolled in this trial:

* Mother is \>18 years at the time of consent
* Mother has diabetes in pregnancy (type 1, type 2 or gestational diabetes)
* Mother intends to breastfeed for at least 6 weeks at the time of consent.
* Infant is born at ≥ 37 weeks and weighs \> 2.5kg
* Clinician caring for infant decides that supplementary nutrition (in addition to maternal breast milk) is required within the first 48 hours after birth.
* Parent/s provide/s a signed and dated informed consent form and has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.

Exclusion Criteria:

Mother/infant pairs meeting any of the following criteria will be excluded from the trial:

* Multiple pregnancy
* Mother has a condition that precludes maternal breast milk consumption e.g. HIV, receiving chemotherapy
* Infant has clinically significant congenital abnormality interfering with effective breastfeeding or breast milk consumption (e.g., cleft lip and palate, metabolic disorder) and/or requiring immediate care in a neonatal unit (e.g., congenital heart disease).
* Infant has received infant formula prior to randomisation.
* Infant admitted to neonatal intensive care prior to randomisation.
* More than 48 hours old at the time of recruitment

Where it's running

  • Frances Perry House (VIC)
    Melbourne, Victoria, Australia
    Recruiting
  • Royal Womens Hospital (VIC)
    Melbourne, Victoria, Australia
    Recruiting
  • Royal Brisbane and Womens Hospital (QLD)
    Brisbane, Queensland, Australia
    Not yet recruiting
  • Greenslope Hospital (QLD)
    Brisbane, Queensland, Australia
    Not yet recruiting

Study contacts

  • Principal investigator: Jennifer Koplin, PhD — Child Health Research Centre, University Of Queensland
  • Study coordinator: Jennifer Koplin, PhD
  • Email: j.koplin@uq.edu.au
  • Phone: 061+0400032577

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.